50 Chapter 2 Predefined specificity 70% Predefined specificity 80% Methylation marker Sensitivity* Cancer detection rate Sensitivity* Cancer detection rate ASCL1 89.1% 50 / 50 84.6% 49 / 50 LHX8 82.9% 50 / 50 74.9% 50 / 50 ST6GALNAC5 73.1% 49 / 50 67.4% 49 / 50 GHSR 73.1% 50 / 50 68.6% 50 / 50 SST 70.3% 50 / 50 65.7% 50 / 50 ZIC1 81.1% 50 / 50 73.7% 49 / 50 Bi-marker panel (ASCL1/LHX8) 89.1% 50 / 50 85.7% 50 / 50 * Sensitivities and specificities are calculated for CIN3 detection. Abbreviations: CIN, cervical intraepithelial neoplasia Table 2.2 Corresponding sensitivity at a predefined specificity of 70% and 80% of six DNA methylation markers (ASCL1, LHX8, ST6GALNAC5, GHSR, SST and ZIC1) and the bi-marker panel (ASCL1/LHX8). ASCL1 0.0 0.0 0.2 0.2 0.4 0.4 0.6 0.6 0.8 0.8 1.0 1.0 1 − Specificity AUC: 0.876 Sensitivity LHX8 0.0 0.0 0.2 0.2 0.4 0.4 0.6 0.6 0.8 0.8 1.0 1.0 1 − Specificity AUC: 0.845 Sensitivity ST6GALNAC5 0.0 0.0 0.2 0.2 0.4 0.4 0.6 0.6 0.8 0.8 1.0 1.0 1 − Specificity AUC: 0.784 Sensitivity GHSR 0.0 0.0 0.2 0.2 0.4 0.4 0.6 0.6 0.8 0.8 1.0 1.0 1 − Specificity AUC: 0.795 Sensitivity SST 0.0 0.0 0.2 0.2 0.4 0.4 0.6 0.6 0.8 0.8 1.0 1.0 1 − Specificity AUC: 0.768 Sensitivity ZIC1 0.0 0.0 0.2 0.2 0.4 0.4 0.6 0.6 0.8 0.8 1.0 1.0 1 − Specificity AUC: 0.836 Sensitivity Figure 2.2 Clinical performance of six single DNA methylation markers (ASCL1, LHX8, ST6GALNAC5, GHSR, SST and ZIC1) for CIN3 detection in HPV-positive women. Cross-validated receiver operating characteristic curves and corresponding AUCs. Abbreviations: AUC, area under the curve; CIN, cervical intraepithelial neoplasia
RkJQdWJsaXNoZXIy MjY0ODMw